Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360 The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback